To evaluate whether serum levels of the soluble form of CD30 (sCD30) correlate with disease activity in early rheumatoid arthritis (RA) and may have prognostic value in predicting the response to disease-modifying anti-rheumatic drugs (DMARDs).
Department of Clinical and Experimental Medicine, Section of Internal Medicine and Oncological Sciences, Centre for the Study of Rheumatic Diseases, University of Perugia, Italy.